NCNathalie Chevallier

Nathalie Chevallier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathalie Chevallier has a total of 197 co-authors. Here are the top co-authors by number of shared publications:

  • Hélène Rouard

    Hôpital Henri Mondor, 94010, Creteil, France

    31 shared publications
  • Charles-Henri Flouzat-Lachaniette

    Department of Orthopaedic Surgery, Hôpital Henri Mondor, AP-HP, Université Paris Est Créteil (UPEC), 94010, Creteil, France; Cell and tissue engineering for musculoskeletal disorders (Group 5) / Biology of the NeuroMuscular System (INSERM Team 10) / Institut Mondor de Recherche Biomédicale, U955 INSERM-UPEC, Créteil, France

    19 shared publications
  • Philippe Hernigou

    Paris-Est Créteil University, Créteil, France

    19 shared publications
  • Yasuhiro Homma

    Hôpital Henri Mondor, 94010, Creteil, France

    9 shared publications
  • Alexandre Poignard

    Université Paris-Est, Faculté de médecine, Laboratoire de "Bioingénierie cellulaire, tissulaire et sanguine", EA3952, Créteil, France; AP-HP Hôpital Henri-Mondor - A. Chenevier, Service hospitalier, Créteil, France

    8 shared publications
  • Philippe Bierling

    Etablissement Français du Sang d'Ile-de-France, Unité d'Ingénierie et de Thérapie Cellulaire, Créteil, France; AP-HP Hôpital Henri-Mondor - A. Chenevier, Service hospitalier, Créteil, France; Inserm UMR955, Créteil, France

    7 shared publications

Latest Publications

  • Open Access

    Directly Thawed Bone Marrow Mesenchymal Stromal Cells Retain Mechanism of Action and Support Bone Clinical Translation

    by Tiffany Marie, Andreea Iuliana Cojocaru, Laura Coquelin, Elina Varaillon, Hélène Rouard, Nathalie Chevallier

    Background Mesenchymal stromal cells (MSCs) are currently employed in numerous clinical protocols, and have been used to enhance the regeneration of bone tissue in case of osteonecrosis, long bone and maxillary bone defects. Traditionally, these protocols were designed using freshly harvested, cultured MSCs. However, several limitations arose due to logistical issues, revealing the need to modify the protocol to facilitate the clinical process. In this context, cryopreservation and the use of the MSCs immediately after thawing seem to be the easiest way to overcome most of these constraints. Methods Bone marrow MSCs (BMSCs) of three donors were compared immediately after harvesting or thawing. First, the kinetics of cell viability and the gene expression profile were assessed in vitro. Then, the role of the cells in supporting vasculogenesis and bone formation in vivo was assessed using molecular biology and histology. Results Firstly, we observed a reduction in cell viability immediately after thawing, but no difference after 2 h. Furthermore, the gene expression profile was equivalent for genes involved in osteoblastic differentiation, vasculogenesis, inflammatory cytokines and proliferation. These in vitro results were confirmed by in vivo assays, which showed that cryopreservation did not affect their inflammatory response or vasculogenesis potential. Additionally, analysis of cell survival kinetics and bone formation assays revealed that cryo- and fresh-BMSCs exhibit equivalent potential to induce new bone formation and participate directly in bone formation, as evidenced by the expression of human osteoblastic genes. Conclusion Our study demonstrated that cryo-BMSCs possess the same properties as fresh BMSCs. Therefore, using cryo-BMSCs appears to be the optimal approach for future bone tissue engineering protocols and will facilitate the establishment of a BMSCs bank for future clinical trials.


  • Open Access

    Synthetic peptides of IL-1Ra and HSP70 have anti-inflammatory activity on human primary monocytes and macrophages: Potential treatments for inflammatory diseases

    by Alba Pensado-López, Aldo Ummarino, Sophia Khan, Anna Guildford, Iain U. Allan, Matteo Santin, Nathalie Chevallier, Elina Varaillon, Elizaveta Kon, Paola Allavena, et al.


  • Open Access

    Human Macrophage- and Osteoclast-Based Constructs Do Not Induce Ectopic Bone Formation

    by Johanna F. A. Husch, Laura Coquelin, Nathalie Chevallier, Natasja W. M. van Dijk, Sander C. G. Leeuwenburgh, Jeroen J. J. P. van Den Beucken

    Purpose: An increasing body of evidence suggests that bone resorbing osteoclasts are important—but as yet underrated—cellular initiators of bone formation. Furthermore, macrophages also have shown stimulatory effects on the osteogenic differentiation of mesenchymal stromal cells (MSCs). Consequently, we here investigated whether human macrophage- and osteoclast-laden carrier materials can induce ectopic bone formation upon subcutaneous implantation in nude mice. Methods: Human osteoclast precursors were isolated and differentiated toward macrophages. Subsequently, these macrophages were seeded onto two types of cell carrier materials (i.e., electrospun polymeric scaffolds and devitalized bovine bone granules) and differentiated for 14 days toward osteoclasts. DNA assay and fluorescent nuclei staining were performed. Osteoclast differentiation was assessed by a tartrate-resistant acid phosphatase (TRAP)-activity assay, TRAP, and immunocytochemical staining for β3 integrin. After 60 days of implantation into nude mice, specimens were retrieved, histologically processed, and stained with hematoxylin and eosin (HE) as well as for TRAP to study ectopic bone formation and osteoclast activity, respectively. Results: Osteoclast precursors limitedly adhered to both material types. Osteoclast-laden samples showed increased intracellular gross TRAP-activity on both cell carrier types, TRAP staining on polymeric electrospun scaffolds, and positive β3 integrin staining on decellularized bovine bone granules compared to the macrophage-laden materials. We observed that only the positive control samples loaded with bone morphogenetic protein-2 (BMP-2) induced ectopic bone formation and TRAP signal. Conclusion: We conclude that neither human macrophage- nor osteoclast-laden constructs are capable to induce ectopic bone formation under the current experimental set-up. Lay summary: Interestingly, increasing amounts of evidence suggest that osteoclasts—the cells responsible for breaking down bone tissue—can trigger bone formation. Therefore, we here aimed to study whether blood-derived macrophages and osteoclasts can induce bone formation in vivo. Consequently, we generated human macrophage- and osteoclast-laden constructs using two types of scaffold materials and implanted them underneath the skin of nude mice. Although we confirmed the presence of macrophages and osteoclasts on the materials, we found no signs of bone formation.


  • Comparison of Osteogenic Capacity and Osteoinduction of Adipose Tissue-Derived Cell Populations

    by Johanna F.A. Husch, Laura Coquelin, Nathalie Chevallier, Dorien M. Tiemessen, Egbert Oosterwijk, René van Rheden, Charlotte Woud, Jurriaan Vossen, Sander C.G. Leeuwenburgh, Jeroen J.J.P. van Den Beucken

    Stromal vascular fraction (SVF) is the primary isolate obtained after enzymatic digestion of adipose tissue that contains various cell types. Its successful application for cell-based construct preparation in an intra-operative setting for clinical bone augmentation and regeneration has been previously reported. However, the performance of SVF-based constructs compared to traditional ex vivo expanded adipose tissue-derived mesenchymal stromal cells (ATMSCs) remains unclear and direct comparative analyses are scarce. Consequently, we here aimed to compare the in vitro osteogenic differentiation capacity of donor-matched SVF versus ATMSCs as well as their osteoinductive capacity. Human adipose tissue from 9 different donors was used to isolate SVF, which was further purified via plastic-adherence to obtain donor-matched ATMSCs. Both cell populations were immunophenotypically characterized for MSC, endothelial and hematopoietic markers after isolation and immunocytochemical staining was used to identify different cell types during prolonged cell culture. Based on normalization using plastic-adherence fraction determination, SVF and ATMSCs were seeded and cultured in osteogenic differentiation medium for 28 days. Furthermore, SVF and ATMSCs were seeded onto devitalized bovine bone granules and subcutaneously implanted into nude mice. After 42 days of implantation, granules were retrieved, histologically processed and stained with hematoxylin and eosin (HE) to assess ectopic bone formation. ATMSCs showed to be a homogenous cell population during cell culture, while SVF cultures consisted of multiple cell types. All donor-matched comparisons showed either accelerated or stronger mineralization for SVF cultures in vitro. However, neither SVF nor ATMSCs loaded on devitalized bone granules induced ectopic bone formation upon subcutaneous implantation, as opposed to control granules loaded with bone morphogenetic protein-2 (BMP-2) which triggered ectopic bone formation with 100% incidence. Despite the observed lack of osteoinduction, our findings provide important in vitro evidence on osteogenic superiority of intra-operatively available SVF as compared to donor-matched ATMSCs. Consequently, further studies should focus on optimizing the efficacy of these cell populations for implementation in orthotopic bone fracture or defect treatment.


  • Open Access

    Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial

    by Enrique Gómez-Barrena, Philippe Rosset, Florian Gebhard, Philippe Hernigou, Nicola Baldini, Helène Rouard, Luc Sensebé, Rosa M. Gonzalo-Daganzo, Rosaria Giordano, Norma Padilla-Eguiluz, et al.


  • History of concentrated or expanded mesenchymal stem cells for hip osteonecrosis: is there a target number for osteonecrosis repair?

    by Philippe Hernigou, Gilles Guerin, Yasuhiro Homma, Arnaud Dubory, Nathalie Chevallier, Hélène Rouard, Charles Henri Flouzat Lachaniette

    Despite multiple possible treatments, the risk of collapse remains the main problem of osteonecrosis. Heart failure (HF). In an effort to address the reverse this issue, curative strategies with regenerative medicine are increasingly being considered. The aim of this technology is to halt or reverse progression of the disease to collapse.


  • Cell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of one hundred and twenty five adult patients

    by Philippe Hernigou, Arnaud Dubory, Yasuhiro Homma, Isaac Guissou, Charles Henri Flouzat Lachaniette, Nathalie Chevallier, Hélène Rouard

    Symptomatic osteonecrosis related to corticosteroids has a high risk of progression to collapse in absence of treatment. The purposes of this study were to evaluate the results of autologous bone marrow grafting of the symptomatic hip in adult patients with osteonecrosis and to compare the results with core decompression alone in the contralateral symptomatic hip.


  • Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee

    by Philippe Hernigou, Jean Charles Auregan, Arnaud Dubory, Charles Henri Flouzat-Lachaniette, Nathalie Chevallier, Helene Rouard

    Total knee arthroplasty (TKA) implanted in patients with secondary osteonecrosis (ON) related to corticosteroids have relatively poor outcome (20% revision rate) at a mean follow-up of only eight years. With the hypothesis that subchondral bone marrow injection might improve knees in these patients, we evaluated 30 patients who had bilateral knee osteoarthritis with severe joint space narrowing and received TKA in one knee and subchondral bone marrow concentrate injection in the contralateral knee.


  • Open Access

    Inferior In Vivo Osteogenesis and Superior Angiogenesis of Human Adipose-Derived Stem Cells Compared with Bone Marrow-Derived Stem Cells Cultured in Xeno-Free Conditions

    by Meadhbh A. Brennan, Audrey Renaud, Fabien Guilloton, Miryam Mebarki, Valerie Trichet, Luc Sensebé, Frederic Deschaseaux, Nathalie Chevallier, Pierre Layrolle


  • Stem cell therapy in early post-traumatic talus osteonecrosis

    by Philippe Hernigou, Arnaud Dubory, Charles Henri Flouzat Lachaniette, Issam Khaled, Nathalie Chevallier, Helene Rouard

    Avascular necrosis of the talus is one of the most notable complications associated with talar neck fractures with frequent evolution of the osteonecrosis into a difficult arthrodesis. We tested whether the injection of bone marrow mesenchymal stem cells (MSCs) could improve the repair process of the osteonecrosis.